Search Results
Your search for ,foR matches 32687 pages
Showing 30051 - 30100Belinostat Active in Relapsed/Refractory Peripheral T-Cell Lymphoma
In the phase II BELIEF trial reported in the Journal of Clinical Oncology, O’Connor et al found that the pan–histone deacetylase inhibitor belinostat (Beleodaq) produced durable responses in patients with relapsed/refractory peripheral T-cell lymphoma. The study supported the U.S. Food...
DNA Repair Kinase Identified as Key Driver of Metastasis in Prostate Cancer
Researchers at Thomas Jefferson University reported finding a single molecule that appears to be the central regulator driving metastasis in prostate cancer. The study, published by Goodwin et al in Cancer Cell, offers a target for the development of a drug that could prevent metastasis in prostate ...
Smoking Cessation Near Time of Lung Cancer Diagnosis May Improve Survival
Tobacco cessation provided a significant survival benefit for patients with lung cancer who quit smoking shortly before or after diagnosis, despite the severity of the disease. Results of this Roswell Park Cancer Institute–led study were published by Dobson Amato et al in the Journal of...
Stereotactic Body Radiotherapy Yields Similar Outcomes in Patients With Biopsy-Proven vs Radiographically Diagnosed Early-Stage NSCLC
In patients with early-stage non–small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy, outcomes were similar between patients with biopsy-proven lesions and those with radiographically diagnosed disease, according to a study by Fischer-Valuck et al in Tumori Journal....
Meta-Analysis Indicates Benefit of Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer With Small Tumors
In a meta-analysis reported in the Journal of Clinical Oncology, O’Sullivan et al found that adjuvant trastuzumab (Herceptin) was associated with a significant disease-free and overall survival benefit among patients with early HER2-positive hormone receptor–positive and hormone...
Extended-Field Intensity-Modulated Radiation Therapy for Cervical and Endometrial Cancers Does Not Increase Risk of Duodenal Toxicity
Women with cervical or endometrial cancer who require treatment to the para-aortic lymph nodes can safely receive extended-field intensity-modulated radiation therapy without increased risk of duodenal toxicity, according to a study by Xu et al in Practical Radiation Oncology. Extended-Field...
Two-Thirds of Patients With Locally Advanced Laryngeal Cancer Not Receiving Recommended Treatment
Despite findings of previous studies and published guidelines, nearly two-thirds of patients with T4a laryngeal cancer are not receiving a total laryngectomy—the recommended form of treatment—and, as a result, have significantly worse survival rates vs those treated with a total...
Study Finds Breast Cancer Survivors Gain More Weight Than Cancer-Free Women
A prospective study examining weight gain in breast cancer survivors compared with cancer-free women from a familial risk cohort has found that, overall, breast cancer survivors gained significantly more weight than cancer-free women of the same age and menopausal status. According to the study...
FDA Approves Gefitinib for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved gefitinib (Iressa) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an...
Preclinical Studies Demonstrate Activity of Type II JAK2 Inhibitor in B-Cell ALL
Laboratory and animal tests of the type II inhibitor CHZ868, which stabilizes the kinase domain in an inactive conformation, are showing that the compound is highly potent against B-cell acute lymphoblastic leukemias (ALLs) with CRLF2 rearrangements. When combined with dexamethasone, CHZ868 induced ...
Disparities in Use of Breast-Conserving Therapy for Early-Stage Breast Cancer
In a study using National Cancer Data Base data reported in JAMA Surgery, Lautner et al identified several factors associated with the use of breast-conserving therapy in women with early-stage breast cancer, including older age, higher education and income, private insurance, treatment at an...
Treatment With PI3K Inhibitors May Cause Cancers to Become More Aggressive and Metastatic
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only ...
Similar Long-Term Outcomes With Robotic vs Traditional Surgery in Patients With Bladder Cancer
In the largest multi-institutional study to date, patients diagnosed with bladder cancer and treated with robot-assisted surgery experienced similar results to those who underwent a traditional open operation, according to research led by scientists at Roswell Park Cancer Institute (RPCI). The ...
Diagnosis of Additional Small Breast Cancers Suggests Screening Mammography May Lead to Overdiagnosis
A study of screening mammography across U.S. counties found that “the clearest result of mammography screening is the diagnosis of additional small cancers” but without a “concomitant decline in the detection of larger cancers, which might explain the absence of any significant...
Modeling Indicates Greater Benefit Without Greater Cost for Increased Colorectal Adenoma Detection Rate in Colonoscopy Screening
In a study reported in JAMA by Meester et al, microsimulation modeling of data from a U.S. community-based health-care system showed that colorectal cancer incidence and mortality were reduced with increased adenoma detection rate in colonoscopy screening, with no increase in total costs. Study...
Early Relapse of Follicular Lymphoma After R‑CHOP Associated With Increased Mortality
In an analysis from the National LymphoCare Study reported in the Journal of Clinical Oncology, Casulo et al found that disease progression within 2 years of diagnosis was associated with increased mortality risk after first-line R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin,...
Addition of Bevacizumab to Standard Chemotherapy Does Not Improve Overall Survival in Newly Diagnosed Ovarian Cancer
Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Oza et al indicate no significant increase with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer. However, overall survival benefit of...
Early Study Suggests Which Glioblastoma Patients May Benefit From Dasatinib
Clinicians testing the drug dasatinib (Sprycel), approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical...
DNA Shed From Head and Neck Tumors Detected in Blood and Saliva
On the hunt for better cancer screening tests, Johns Hopkins scientists led a proof-of-principle study that successfully identified tumor DNA shed in the blood and saliva of 93 patients with head and neck cancer. A report on the findings was published by Wang et al in Science Translational...
Breastfeeding Associated With Reduced Risk of Breast Cancer Recurrence and Mortality in Luminal A Subtype
In a study reported in the Journal of the National Cancer Institute, Kwan et al found that women with basal-like tumors were less likely to have breastfed than those with luminal A tumors and that breastfeeding was associated with a significantly reduced risk of recurrence and breast...
Pembrolizumab Increases Progression-Free Survival vs Chemotherapy in Ipilimumab-Refractory Advanced Melanoma
In the randomized phase II KEYNOTE-002 trial reported in The Lancet Oncology, Ribas et al found that treatment with the anti–PD-1 antibody pembrolizumab (Keytruda) prolonged progression-free survival vs investigator-choice chemotherapy in patients with advanced melanoma progressing on...
Protein-Enriched Exosome Useful for Early Diagnosis of Pancreatic Cancer
A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential noninvasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study completed by University of Texas MD...
Study Finds More Selective Ordering of Breast Biomarker Tests Could Save Millions in Health-Care Dollars
A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health-care spending without compromising care, according to Johns Hopkins researchers. Specifically,...
ASCO Endorses ASTRO Guideline on Radiation Therapy After Surgery for Endometrial Cancer
The American Society of Clinical Oncology (ASCO) issued an endorsement of the American Society for Radiation Oncology (ASTRO) clinical practice guideline on postoperative radiation therapy for women with endometrial (uterine) cancer. The endorsement was published by Meyer et al in the Journal of...
Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction Associated With Risk of Melanoma
In a study in Swedish men reported in JAMA, Loeb et al found a statistically significant increase in risk of malignant melanoma in those using oral phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction. However, risk was not significantly elevated in men filling multiple PDE5...
Community-Based Trial Suggests No Benefit of Adding Thalidomide or Melphalan to Bortezomib-Based First-Line Treatment of Myeloma
In the U.S. community-based phase IIIB UPFRONT trial reported in the Journal of Clinical Oncology, Niesvizky et al found no benefit of adding thalidomide (Thalomid) or melphalan to first-line bortezomib (Velcade)-based treatment in transplant-ineligible myeloma patients. Study Details In the...
Daratumumab Expanded Access Program Open to Eligible U.S. Patients With Heavily Pretreated Multiple Myeloma
Janssen Biotech, Inc, announced the opening of a daratumumab expanded access program for eligible U.S. patients. Daratumumab is an investigational human anti-CD38 monoclonal antibody being evaluated in clinical trials as a treatment for patients with multiple myeloma. The multicenter, open-label...
Mapping Genetic Mutations in Cutaneous Melanoma
Researchers have a significantly better understanding of the genetic alterations found in cutaneous melanoma as part of a multi-institution, international effort of The Cancer Genome Atlas (TCGA). The study, published in Cell, refined and revealed new molecular subgroups of patients who could...
Study Identifies Geographic Hot Spots With the Highest Colorectal Cancer Death Rates
Gains have been made in the overall reduction in the death rates of colorectal cancer in the United States. A new study by Siegel et al has identified three distinct geographic hot spots where colorectal cancer death rates remain elevated over other parts of the country. These hot spots were found...
Risk Factors for Interval Invasive Second Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Lee et al found that factors associated with an increased risk of interval second breast cancers after negative surveillance mammography included grade II primary breast cancer, lumpectomy without radiation, interval primary...
Earlier Palliative Care Consultation Associated With Cost Savings
In a prospective cohort study reported in the Journal of Clinical Oncology, May et al found that earlier palliative care consultation for inpatients with advanced cancer was associated with lower total direct costs. Study Details The study included 969 patients with advanced cancer admitted to 5...
Postoperative Radiation Therapy May Improve Overall Survival in Incompletely Resected Stage II or III NSCLC
In a National Cancer Data Base analysis reported in the Journal of Clinical Oncology, Wang et al found that postoperative radiation therapy has been declining in use in recent years but is associated with improved overall survival in patients with incompletely resected stage II or III...
ESMO World GI 2015: Second-Line Cetuximab Active Beyond Progression in Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer that are free of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes showed a significant benefit from continuing antiepidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody. ...
ESMO World GI 2015: Studies Confirm Regorafenib Benefit in Pretreated Metastatic Colorectal Cancer
The phase IIIb CONSIGN trial has confirmed the benefit of regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer, researchers announced July 3 at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona, Spain (Abstract...
Molecular Classification of Glioma Based on IDH Mutation, 1p/19q Codeletion, and TERT Promoter Mutation Status
In a study reported in The New England Journal of Medicine, Eckel-Passow et al identified a molecular classification scheme for gliomas based on IDH mutation, codeletion of chromosome arms 1p and 19q (1p/19q codeletion), and TERT promoter mutation status. Molecular Classification The study...
Chinese Study Finds Serum MicroRNA Classifier Better Than Alpha-Fetoprotein for Early Detection of Hepatocellular Carcinoma
In a study reported in The Lancet Oncology, Lin et al developed a serum microRNA classifier that was more accurate than alpha-fetoprotein in detecting preclinical hepatocellular carcinoma. Study Details The study involved healthy controls, inactive hepatitis B surface antigen carriers,...
MASCC/ISOO 2015: Phase III Study of Single-Dose Fosaprepitant Dimeglumine in Prevention of Chemotherapy-Induced Nausea and Vomiting
Researchers from Merck presented results from a phase III study investigating the safety and efficacy of single-dose fosaprepitant dimeglumine (Emend) for injection, a neurokinin-1 receptor antagonist, in combination with other antivomiting medicines, for the prevention of chemotherapy-induced...
Better Outcome With Paclitaxel vs Nab-Paclitaxel or Ixabepilone Plus Bevacizumab in First-Line Treatment of Advanced Breast Cancer
In the phase III CALGB 40502/NCCTG N063H/Alliance trial reported in the Journal of Clinical Oncology, Rugo et al found that outcomes in first-line treatment for advanced breast cancer were better with weekly paclitaxel plus bevacizumab (Avastin) compared with weekly nanoparticle albumin-bound...
MASCC/ISOO 2015: Data Show Disconnect Between Clinician and Patient Perceptions of Treatment-Induced Nausea and Vomiting
Researchers from Norgine B.V. presented new data highlighting a perceptual gap between health-care professionals and patients in terms of the incidence and impact on patients’ daily life of chemotherapy- and radiotherapy-induced nausea and vomiting (CINV/RINV) at the joint Multinational...
Phase II Trial Shows Activity of mTOR Inhibitor Ridaforolimus in Advanced Endometrial Carcinoma
In a randomized phase II trial reported in the Journal of Clinical Oncology, Oza et al found that the mTOR inhibitor ridaforolimus was active in previously treated advanced endometrial carcinoma. Study Details In the open-label study, 130 patients with progressive disease after one or two lines...
Survival Benefit of Surgery Lower for Low-Grade vs Higher-Grade Ductal Carcinoma in Situ
In a population-based cohort study reported in JAMA Surgery, Sagara et al found that the breast cancer–specific survival benefit associated with surgery for low-grade ductal carcinoma in situ is lower than that associated with surgery for intermediate- or high-grade ductal carcinoma in situ. ...
ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy
The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....
ESMO World GI 2015: Low Body Mass Index Associated With Poorer Survival in Metastatic Colorectal Cancer
Although being overweight with a high body mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well as previously expected after treatment for advanced cancer, according to a new study from Duke Medicine. The study, which was...
Differences in Patient-Reported Outcomes but Not Global Quality of Life With Exemestane vs Tamoxifen in Early Breast Cancer With Ovarian Suppression
In a pooled analysis of the TEXT and SOFT trials reported in The Lancet Oncology, Bernhard et al found no difference in global quality of life with exemestane vs tamoxifen in women with early breast cancer undergoing ovarian suppression. The two agents were associated with differences in specific...
No Benefit of Adding CT to Basic Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism
In a Canadian study reported in The New England Journal of Medicine, Carrier et al found that adding computed tomography (CT) of the abdomen and pelvis to basic screening did not improve detection of occult cancers in patients with a first episode of unprovoked venous thromboembolism. Venous...
Low Axillary Recurrence/Mortality Among Older Women With Node-Negative Breast Cancer Undergoing Breast-Conserving Surgery Without Sentinel Node Biopsy
In a single institution study reported in JAMA Surgery, Chung et al found a low axillary recurrence rate and low mortality among women with clinical T1–2N0 breast cancer aged ≥ 70 years who underwent breast-conserving surgery without sentinel node biopsy. Study Details The study involved ...
Development of New Blood Vessels Not Essential to Growth of Lymph Node Metastases
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital (MGH) Cancer Center may have...
New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment
Metastatic colorectal cancer patients have improved survival rates when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapeutic agents before they begin treatment, researchers at University of California (UC) San Diego...
Four-Gene Model Predicts Response to Aromatase Inhibitor Therapy for Breast Cancer
As reported in the Journal of Clinical Oncology, Turnbull et al identified a four-gene predictive model of response to aromatase inhibitor therapy that was highly predictive of response on the basis of pretreatment and 2-week on-treatment measurements. The classifier was a significant predictor of...
Phase II Trial Indicates No Benefit of Sorafenib, Temsirolimus, or Bevacizumab Doublets vs Bevacizumab Alone in Advanced Renal Cell Carcinoma
In a randomized phase II trial (BEST; ECOG-ACRIN E2804) reported in the Journal of Clinical Oncology, Flaherty et al found that adding the VEGFR inhibitor sorafenib (Nexavar) or the mTOR inhibitor temsirolimus (Torisel) to the VEGF inhibitor bevacizumab (Avastin) or using sorafenib-temsirolimus in...
